150 related articles for article (PubMed ID: 15254920)
1. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.
Dautzenberg PL; Mulder LJ; Olde Rikkert MG; Wouters CJ; Loonen AJ
Int J Geriatr Psychiatry; 2004 Jul; 19(7):641-4. PubMed ID: 15254920
[TBL] [Abstract][Full Text] [Related]
2. [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].
Kalisvaart CJ; Boelaarts L; de Jonghe JF; Hovinga IM; Kat MG
Ned Tijdschr Geneeskd; 2004 Jul; 148(30):1501-4. PubMed ID: 15481575
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
Dautzenberg PL; Wouters CJ; Oudejans I; Samson MM
Int J Geriatr Psychiatry; 2003 Jun; 18(6):555-6. PubMed ID: 12789683
[No Abstract] [Full Text] [Related]
4. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
5. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
6. [Co-morbidity in acutely hospitalised older patients as a risk factor for death in hospital or within 3 months after discharge].
de Rooij SE; Buurman BM; korevaar JC; Van Munster BC; Schuurmans MJ; Laqaaij AM; Verhaar HJ; Levi M
Ned Tijdschr Geneeskd; 2007 Sep; 151(36):1987-93. PubMed ID: 17953173
[TBL] [Abstract][Full Text] [Related]
7. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
[TBL] [Abstract][Full Text] [Related]
8. [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].
van den Bliek BM; Maas HA
Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2149; author reply 2149. PubMed ID: 15553363
[No Abstract] [Full Text] [Related]
9. Adding rivastigmine to antipsychotics in the treatment of a chronic delirium.
Dautzenberg PL; Mulder LJ; Olde Rikkert MG; Wouters CJ; Loonen AJ
Age Ageing; 2004 Sep; 33(5):516-7. PubMed ID: 15315924
[No Abstract] [Full Text] [Related]
10. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Mol JA
Ned Tijdschr Geneeskd; 2003 Apr; 147(14):679; author reply 679. PubMed ID: 12712655
[No Abstract] [Full Text] [Related]
11. Clinical characteristics and risk factors of delirium in demented and not demented elderly medical inpatients.
Margiotta A; Bianchetti A; Ranieri P; Trabucchi M
J Nutr Health Aging; 2006; 10(6):535-9. PubMed ID: 17183425
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
[TBL] [Abstract][Full Text] [Related]
13. [Ethical aspects of anti-Alzheimer drugs: experiences of caregivers].
Huizing AR; Berghmans RL; Widdershoven GA; Verhey FR
Tijdschr Gerontol Geriatr; 2002 Dec; 33(6):246-51. PubMed ID: 12611287
[TBL] [Abstract][Full Text] [Related]
14. Does home treatment affect delirium? A randomised controlled trial of rehabilitation of elderly and care at home or usual treatment (The REACH-OUT trial).
Caplan GA; Coconis J; Board N; Sayers A; Woods J
Age Ageing; 2006 Jan; 35(1):53-60. PubMed ID: 16239239
[TBL] [Abstract][Full Text] [Related]
15. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
Fischer P
J Clin Psychopharmacol; 2001 Feb; 21(1):118. PubMed ID: 11199939
[No Abstract] [Full Text] [Related]
17. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
18. Validation of a German version of the Confusion Assessment Method for delirium detection in a sample of acute geriatric patients with a high prevalence of dementia.
Hestermann U; Backenstrass M; Gekle I; Hack M; Mundt C; Oster P; Thomas C
Psychopathology; 2009; 42(4):270-6. PubMed ID: 19521144
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine in the treatment of alcohol-induced persisting dementia.
Gibson RC; Barnaby L
West Indian Med J; 2003 Mar; 52(1):59-61. PubMed ID: 12806761
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
Farlow MR; Lilly ML;
BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
